Zi-Factor, 500 mg 3 pcs

Zi Factor is antibacterial.

When creating high concentrations in the focus of inflammation it has a bactericidal effect.

Pharmacodynamics

The spectrum of action is broad and includes Gram-positive cocci: Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus groups CF and G, Staphylococcus aureus, Staphylococcus viridans, Gram-negative bacteria Haemophilus influenzae, Moraxella catarrhalis, Bordetella pertussis, Bordetella parapertussis, Legionella pneumophila, H. ducreyi, Campylobacter jejuni, Neisseria gonorrhoeae, Gardnerella vaginalis, some anaerobic microorganisms: Bacteroides bivius, Clostridium perfringens, Peptostreptococcus spp, as well as Chlamydia trachomatis, Mycoplasma pneumoniae, Ureaplasma urealyticum, Treponema pallidum, Borrelia burgdorferi. It is inactive against Gram-positive bacteria resistant to erythromycin.

Pharmacokinetics

Stable in acidic environment, lipophilic, rapidly absorbed in the gastrointestinal tract. After oral administration at a dose of 500 mg, C_max in plasma is 0.4 mg/L and is reached after 2.5-2.96 h. Bioavailability is 37%.

It penetrates well into the respiratory tract, organs and tissues of the urogenital tract (in particular the prostate gland), skin and soft tissue. Concentration in tissues and cells is 10-50 times higher than in plasma, and in infection foci it is 24-34% higher than in healthy tissues (correlates with the degree of inflammatory edema).

Transported by phagocytes to the focus of infection, where it is released during phagocytosis. The apparent volume of distribution is 31.1 l/kg. High antibacterial level is maintained in the focus of inflammation for 5-7 days.

Metabolized in the liver by demethylation with the formation of inactive metabolites.

The excretion is in 2 steps; T_1/2 is 14-20 h (between 8-24 h after drug administration) and 41 h (between 24-72 h).

Indications

Infections of the upper (pharyngitis, tonsillitis) and lower (bacterial and atypical pneumonia, bronchitis) airways, ENT organs (otitis media, sinusitis), skin and soft tissue (rye, impetigo, secondary infected dermatoses), urogenital tract (uncomplicated urethritis and/or cervicitis), Lyme disease (treatment of erythema migrans), diseases of the stomach and duodenum associated with Helicobacter pylori (in combination therapy).

Active ingredient

Composition

Active ingredient:

azithromycin dihydrate (in terms of azithromycin) 500 mg;

Auxiliary substances:

calcium phosphate dihydrate;

sodium lauryl sulfate;

povidone;

crospovidone;

magnesium stearate;

Shell:

oxypropyl methylcellulose;

titanium dioxide;

povidone;

tulk;

twin-80 (polysorbate);

acid red dye

How to take, the dosage

Orally, 1 hour before or 2 hours after a meal once a day.

In adults with upper and lower respiratory tract infections – 500 mg/day for 3 days (course dose – 1500 mg);

In cases of infections of the skin and soft tissue – 1000 mg/day for the first day, further (days 2-5) 500 mg/day (the course dose – 3000 mg); in acute infections of the urogenital tract (uncomplicated urethritis or cervicitis) – 1000 mg once;

In Lyme disease (treatment of the initial stage – erythema migrans) – 1000 mg/day on the first day, further (days 2-5) – 500 mg/day (cumulative dose – 3000 mg);

I have been administered intravenous lyme disease and the course dose is 3000 mg.

In gastric and duodenal ulcer associated with Helicobacter pylori – 1000 mg/day for 3 days in combination therapy.

In children – 10 mg/kg of body weight during 3 days or 10 mg/kg during the first day and then 5 mg/kg/day for 4 days (the course dose – 30 mg/kg), in case of erythema migrans treatment – 20 mg/kg during the first day, further (days 2-5) 10 mg/kg.

Interaction

Antacids (aluminum and magnesium-containing), ethanol, and food slow down and decrease absorption.

Increases digoxin concentration, slows excretion and increases plasma concentration and toxicity of cyclosporine, indirect anticoagulants, methylprednisolone, felodipine, carbamazepine, terfenadine, hexobarbital, ergot alkaloids, valproic acid, disopyramide, bromocriptine, phenytoin, oral hypoglycemic agents, theophylline and other xanthine derivatives.

Lincosamides impair efficacy, tetracycline and chloramphenicol enhance it. Pharmaceutically incompatible with heparin.

Special Instructions

A break of 2 hours should be observed when concomitant use of antacids.

Hypersensitivity reactions may persist in some patients after treatment withdrawal, which requires specific therapy under medical supervision.

Contraindications

Hypersensitivity (including to other macrolides), hepatic and/or renal insufficiency, breastfeeding, infant age less than 1 year.

Side effects

Nervous system and sensory organs: ≤1% – dizziness, headache, somnolence; in children – hyperkinesia, anxiety, neurosis, sleep disorders.

Cardiovascular system and blood (hematopoiesis, hemostasis): ≤1% – palpitation, pain in the chest.

Gastrointestinal system disorders: diarrhea (5%), nausea, abdominal pain (3%); ≤1% – dyspepsia, flatulence, vomiting, melena, cholestatic jaundice, increased liver transaminases activity; in children – constipation, anorexia, gastritis.

Urogenital system disorders: ≤1% – vaginal candidiasis, nephritis.

Allergic reactions: rash, photosensitization, Quincke’s edema.

Others: increased fatigue, in children – conjunctivitis, itching, urticaria.

Overdose

Symptoms: severe nausea, temporary hearing loss, vomiting, diarrhea.

Pregnancy use

Possible if the expected effect of therapy exceeds the potential risk to the fetus.

Breastfeeding should be stopped during treatment.

Similarities